434 related articles for article (PubMed ID: 17072331)
1. Mutations in the NF-kappaB signaling pathway: implications for human disease.
Courtois G; Gilmore TD
Oncogene; 2006 Oct; 25(51):6831-43. PubMed ID: 17072331
[TBL] [Abstract][Full Text] [Related]
2. NF-kappaB-related genetic diseases.
Courtois G; Smahi A
Cell Death Differ; 2006 May; 13(5):843-51. PubMed ID: 16397577
[TBL] [Abstract][Full Text] [Related]
3. NF-kappaB and inflammation in genetic disease.
Sebban H; Courtois G
Biochem Pharmacol; 2006 Oct; 72(9):1153-60. PubMed ID: 16965764
[TBL] [Abstract][Full Text] [Related]
4. NF-kappaB signaling pathway and its therapeutic implications in human diseases.
Sarkar FH; Li Y; Wang Z; Kong D
Int Rev Immunol; 2008; 27(5):293-319. PubMed ID: 18853341
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the TLR/NF-kappaB pathway in antigen-presenting cells in malignancies promoted by inflammation.
Blander JM
Methods Mol Biol; 2009; 512():99-117. PubMed ID: 19347275
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of NF-kappaB signaling: 785 and counting.
Gilmore TD; Herscovitch M
Oncogene; 2006 Oct; 25(51):6887-99. PubMed ID: 17072334
[TBL] [Abstract][Full Text] [Related]
7. Advances in NF-kappaB signaling transduction and transcription.
Xiao W
Cell Mol Immunol; 2004 Dec; 1(6):425-35. PubMed ID: 16293211
[TBL] [Abstract][Full Text] [Related]
8. Human disease resulting from gene mutations that interfere with appropriate nuclear factor-kappaB activation.
Orange JS; Levy O; Geha RS
Immunol Rev; 2005 Feb; 203():21-37. PubMed ID: 15661019
[TBL] [Abstract][Full Text] [Related]
9. Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models.
Gerondakis S; Grumont R; Gugasyan R; Wong L; Isomura I; Ho W; Banerjee A
Oncogene; 2006 Oct; 25(51):6781-99. PubMed ID: 17072328
[TBL] [Abstract][Full Text] [Related]
10. Regulating the regulator: NF-kappaB signaling in heart.
Hall G; Hasday JD; Rogers TB
J Mol Cell Cardiol; 2006 Oct; 41(4):580-91. PubMed ID: 16949095
[TBL] [Abstract][Full Text] [Related]
11. Regulation of NF-kappaB transcriptional activity.
Vermeulen L; Vanden Berghe W; Haegeman G
Cancer Treat Res; 2006; 130():89-102. PubMed ID: 16610704
[TBL] [Abstract][Full Text] [Related]
12. Temporal and spatial profiling of nuclei-associated proteins upon TNF-alpha/NF-kappaB signaling.
Ma DJ; Li SJ; Wang LS; Dai J; Zhao SL; Zeng R
Cell Res; 2009 May; 19(5):651-64. PubMed ID: 19399029
[TBL] [Abstract][Full Text] [Related]
13. Ras effector pathways modulate scatter factor-stimulated NF-kappaB signaling and protection against DNA damage.
Fan S; Meng Q; Laterra JJ; Rosen EM
Oncogene; 2007 Jul; 26(33):4774-96. PubMed ID: 17297451
[TBL] [Abstract][Full Text] [Related]
14. Wnt/beta-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-kappaB activation in cancer cells.
Du Q; Zhang X; Cardinal J; Cao Z; Guo Z; Shao L; Geller DA
Cancer Res; 2009 May; 69(9):3764-71. PubMed ID: 19383900
[TBL] [Abstract][Full Text] [Related]
15. Hypoxic regulation of NF-kappaB signaling.
Cummins EP; Comerford KM; Scholz C; Bruning U; Taylor CT
Methods Enzymol; 2007; 435():479-92. PubMed ID: 17998070
[TBL] [Abstract][Full Text] [Related]
16. Dynamic protein complexes regulate NF-kappaB signaling.
Wegener E; Krappmann D
Handb Exp Pharmacol; 2008; (186):237-59. PubMed ID: 18491055
[TBL] [Abstract][Full Text] [Related]
17. Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism.
Gupta V; Yeo G; Kawakubo H; Rangnekar V; Ramaswamy P; Hayashida T; MacLaughlin DT; Donahoe PK; Maheswaran S
Cancer Res; 2007 Mar; 67(6):2747-56. PubMed ID: 17363596
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of mutations in hepatitis C virus core protein associated with alteration of NF-kappaB activation.
Mann EA; Stanford S; Sherman KE
Virus Res; 2006 Oct; 121(1):51-7. PubMed ID: 16723161
[TBL] [Abstract][Full Text] [Related]
19. Dimeric procyanidin B2 inhibits constitutively active NF-kappaB in Hodgkin's lymphoma cells independently of the presence of IkappaB mutations.
Mackenzie GG; Adamo AM; Decker NP; Oteiza PI
Biochem Pharmacol; 2008 Apr; 75(7):1461-71. PubMed ID: 18275936
[TBL] [Abstract][Full Text] [Related]
20. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
